Compare ASTRAZENECA PHARMA with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs TTK HEALTHCARE - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA TTK HEALTHCARE ASTRAZENECA PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 108.7 25.8 421.8% View Chart
P/BV x 14.6 3.6 402.8% View Chart
Dividend Yield % 0.1 0.8 9.5%  

Financials

 ASTRAZENECA PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-21
TTK HEALTHCARE
Mar-21
ASTRAZENECA PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,970670 742.0%   
Low Rs2,348313 749.7%   
Sales per share (Unadj.) Rs325.4450.5 72.2%  
Earnings per share (Unadj.) Rs37.332.9 113.5%  
Cash flow per share (Unadj.) Rs45.442.6 106.6%  
Dividends per share (Unadj.) Rs2.006.00 33.3%  
Avg Dividend yield %0.11.2 4.5%  
Book value per share (Unadj.) Rs181.8208.5 87.2%  
Shares outstanding (eoy) m25.0014.13 176.9%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x11.21.1 1,030.5%   
Avg P/E ratio x98.015.0 655.6%  
P/CF ratio (eoy) x80.611.5 698.5%  
Price / Book Value ratio x20.12.4 853.7%  
Dividend payout %5.418.3 29.4%   
Avg Mkt Cap Rs m91,4786,945 1,317.2%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1951,601 137.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m8,1366,365 127.8%  
Other income Rs m128100 128.4%   
Total revenues Rs m8,2646,465 127.8%   
Gross profit Rs m1,355430 315.1%  
Depreciation Rs m201137 146.8%   
Interest Rs m1122 49.0%   
Profit before tax Rs m1,271371 343.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m338-94 -359.9%   
Profit after tax Rs m933464 200.9%  
Gross profit margin %16.76.8 246.6%  
Effective tax rate %26.6-25.3 -104.9%   
Net profit margin %11.57.3 157.2%  
BALANCE SHEET DATA
Current assets Rs m6,8873,752 183.5%   
Current liabilities Rs m3,7341,888 197.8%   
Net working cap to sales %38.829.3 132.3%  
Current ratio x1.82.0 92.8%  
Inventory Days Days4515 293.7%  
Debtors Days Days38343 11.2%  
Net fixed assets Rs m1,8551,126 164.8%   
Share capital Rs m50141 35.4%   
"Free" reserves Rs m4,4962,805 160.3%   
Net worth Rs m4,5462,946 154.3%   
Long term debt Rs m00-   
Total assets Rs m8,7424,878 179.2%  
Interest coverage x117.617.7 665.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 71.3%   
Return on assets %10.810.0 108.2%  
Return on equity %20.515.8 130.2%  
Return on capital %28.213.3 211.5%  
Exports to sales %05.0 0.0%   
Imports to sales %29.30.4 8,012.6%   
Exports (fob) Rs mNA318 0.0%   
Imports (cif) Rs m2,38223 10,240.8%   
Fx inflow Rs m318318 100.0%   
Fx outflow Rs m2,38241 5,842.5%   
Net fx Rs m-2,064277 -745.6%   
CASH FLOW
From Operations Rs m1,048964 108.7%  
From Investments Rs m1,730-772 -224.0%  
From Financial Activity Rs m-90-172 52.3%  
Net Cashflow Rs m2,68820 13,269.5%  

Share Holding

Indian Promoters % 0.0 74.6 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.6 4.8 74.4%  
FIIs % 2.4 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 25.4 98.3%  
Shareholders   57,760 15,817 365.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex, Nifty End Marginally Lower; Metal Stocks Witness Selling(Closing)

After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.

Related Views on News

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

IPO Alert! 3 Companies Including PharmEasy Get the Green Light (Views On News)

Feb 22, 2022

The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 23, 2022 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS